Author: media manager

16 Dec

Posted at 16:56h in Blog

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has published a draft version of General Chapter 5.38 “Quality of Data,” which is now open for public review and can be commented on until 31 December 2024.

Impact of Technological Advancements

The draft of the new chapter refers to data generated, collected, stored, or used in the context of experimental analyses performed by quality control (QC) laboratories and highlights their increasing importance in relation to the quality assessment of medicines, particularly when these data are fed into numerical models based on chemometrics, machine learning (ML), or other forms of artificial intelligence (AI) in order to make inferences, make decisions and take action.

In this context, a defined quality standard must be applied and ensured.

Scope 

The purpose of this chapter is to focus on the “raw material” of data analysis, providing an overview of applicable data quality concepts, describing best practices for achieving a sufficiently high data quality, and reporting a summary of data governance procedures.

Quality of Data 

The text defines data as a collection of values, as “data elements” or “unit of data” with specific meaning derived from its context, including the source and generation processes.

Data elements can be classified into:

  • Primitive types (e.g., Boolean, , integers, real values, characters)
  • Composite, structured types (e.g., arrays, tables)
  • Unstructured types, not following a predefined format (e.g., text documents, natural language)

You can view and comment on the draft of chapter “5.38. QUALITY OF DATA” at: https://pharmeuropa.edqm.eu/home.

Latest posts

Back to all posts

Have questions on what Chemsafe can do for you?

01 Oct

Posted at 09:45h in Blog

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has recently published updated versions of three water monographs in the European Pharmacopoeia (Ph.Eur.):

  • Water for injections (0169)
  • Purified water (0008)
  • Total organic carbon (TOC) in water for pharmaceutical use (2.2.44)

The updates include some key clarifications:

 

Water for Injection (0169)

TOC Limit Adjustment: to reduce ambiguity, the upper limit for Total Organic Carbon (TOC) has been restricted from 0.5 mg/L to 0.50 mg/L.

Testing Requirements: the requirement to test oxidisable substances (OS) in “Sterilized Water for Injection” (SWFI) has been superseded by the introduction of the mandatory use of the total organic carbon (TOC) method B. This change simplifies the testing procedure by focusing solely on TOC measurements.

The TOC test is a state-of-the-art quantitative method that is more sensitive and non-selective than the OS test for the control of organic impurities present in pharmaceutical waters.

Residue on Evaporation: the “Residue on Evaporation” test, which measures non-volatile residue, has been changed from percentage to parts per million (ppm), offering a more standardized expression of the results.

 

Purified Water (0008)

Harmonization with WFI Standards: the TOC limit for Purified Water has also been aligned with the update to Water for Injection, now set at a 0.50 mg/L.

Standardized Units: for “Purified Water in Containers,” the measurement unit for “Residue on Evaporation” has changed from percentage to ppm, standardizing the way results are reported.

 

Total Organic Carbon in Water for Pharmaceutical Use (2.2.44)

Clarification of Water Specifications: the term “highly purified water” has been replaced with “water,” which corresponds to the specifications conductivity LF of ≤ 1.0 µS/cm at 25 °C and a TOC level of ≤ 0.1 mg/L.

Moreover, in the proposed revision of chapter 2.2.44, the reagents sucrose R and 1,4-benzoquinone R have been replaced by chemical reference substances (CRSs) to streamline the application of the TOC test.

The commenting period runs until 30 September 2024.

 

SOURCES:

The monographs can be found in draft status on the website of the European Pharmacopoeia.

More information on how to comment is available at: “Comment on drafts (Pharmeuropa)”.

Latest posts

Back to all posts

Have questions on what Chemsafe can do for you?

01 Oct

Posted at 09:39h in Blog

The updated guideline will replace the “Note for guidance on chemistry of new active substances – (CPMP/QWP/130/96, Rev 1)” and the “Chemistry of active substances – (3AQ5a)”, it has been revised to cover new and existing active substances in one guideline.

As reported, the Concept paper on the revision of the guideline on the chemistry of active substances” of the Quality Working Party (QWP) was published for comments in June 2022. This document aimed to explain and clarify the need to revise and update the “Guideline on the chemistry of active substances (EMA/454576/2016)” and to outline the procedure for the revision.

The results obtained and insights gained were incorporated into the draft of revision 1 of the “Guideline on the chemistry of active substances,” which was published in July 2024. The draft is now open for public comments until the end of January 2025.

 

As already contemplated in the concept paper, the topic of N-nitrosamine was considered and integrated throughout the text of the guideline

 

SOURCES:

https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-chemistry-active-substances-revision-1_en.pdf

Latest posts

Back to all posts

Have questions on what Chemsafe can do for you?

01 Oct

Posted at 09:34h in Blog

An update of Technical Interpretation I-SMI.TI.17e, Version 7.0 “Responsible person: requirements” has been posted on the webpage on 26.08.2024 (Responsible Person: requirements (I-SMI.TI.17e) (swissmedic.ch).

For the inspectorates, to whom all technical interpretations are primarily addressed, the technical interpretation applies with immediate effect.

Key updates in the new version include clarifications concerning the educational background and knowledge requirements for the Responsible Person (RP), especially in relation to activities that demand Good Distribution Practice (GDP) and/or Good Manufacturing Practice (GMP) experience.

To ensure compliance with the new technical interpretation the licence holder is generally required to conduct a gap analysis in order to adapt immediately to the additional requirements.

Chapter 5.2 Experience states that “GDP experience is required for the import and/or wholesale with or without market release activities, as well as export, brokerage- and/or agent activities and/or trade in foreign countries”.

The same chapter also specifies that “Brokerage, agents and trade in foreign countries-activities do not count as GDP experience for the assumption of a function as a responsible person in a company with import, export and/or wholesale activities”.

In addition, a Swissmedic press release highlights a requirement outlined in Chapter 5.5. “Chapter 5.5 requires a good knowledge of the local language for the responsible person. Establishment licence holders whose already approved responsible person does not meet these requirements are given a period of 12 months from the date of publication of the updated technical interpretation to make the necessary adjustments, either by appointing a new responsible person with the required language skills or by ensuring that the responsible person acquires the required language skills within this period”.

 

 

SOURCES:

Inspectorates website.

Latest posts

Back to all posts

Have questions on what Chemsafe can do for you?

01 Oct

Posted at 09:27h in Blog

USP General Chapter <41> Balances establishes the requirements for balances used for materials that are to be accurately weighed. Weighing must be done with a balance that is calibrated over the operating range and meets the defined requirements for Repeatability and Accuracy.

This proposal is based on the official version dated August 1, 2019. The proposal published in PF 49(5) [September-October 2023], has been cancelled and is being replaced by this new one.

The proposed changes gather comments received from stakeholders and are intended to align with Weighing on an Analytical Balance 〈1251〉 as well as the European Pharmacopoeia chapter “Balances for Analytical Purposes”.

In addition to formal changes, updates and additions were made in the following areas:

  1. Introduce the relationship between calibration and performance checks within the life cycle approach to ensure fitness for purpose.
  2. Include the concept of a risk-based approach with respect to the frequency of calibration and performance checks.
  3. Add a new section on Calibration, clarifying its purpose and including considerations for uncertainty and frequency.
  4. Introduce clarifications of compliance with respect to the Repeatability
  5. Align the term minimum weightwith that in 〈1251〉 and in the European Pharmacopoeia, with regard to standard deviation. Include calculation examples.
  6. Introduce text that differentiates the minimum weightfrom the smallest net weight.
  7. Clarify criteria to ensure compliance with the required accuracy during performance test checks and calibration, including consideration of the uncertainty of the test weights.
  8. Incorporate additional applicable references into the text.

Comments and observations on these drafts can be submitted until 30 November 2024.

 

USP General Chapter 〈1251〉 Weighing on an Analytical Balance is a guideline applicable to balances used in all analytical procedures. It provides information on installation and operational qualification (IQ/OQ), performance qualification and balance checks (routine testing), minimum weight, and balance operation.

This proposal is based on the version of the official chapter issued on May 1, 2018. The previous proposal, published in PF 49(5) [September-October 2023], has been cancelled and is being replaced by this new draft. Based on comments received from stakeholders and to align with Balances 〈41〉 as well as the European Pharmacopoeia chapter “Balances”, the following changes are proposed:

  1. In the Introduction, clarify the group of instruments in which balances are included as per Analytical Instrument Qualification 〈1058〉 and its relationship with the analytical target profile described in Analytical Procedure Life Cycle 〈1220〉.
  2. Add a new section, Principle, defining weight and units.
  3. In Performance Qualification, the risk of the weighing application is explained with regard to the user’s quality management system in order to define the frequency and the type of performance qualification activities.
  4. Discuss the frequency of each of the individual tests included, as well as the relationship between calibration and verification.
  5. Delete the section Balance Checks and integrate it into Performance Qualification.
  6. Simplify the definition of minimum weight and add clarifications about the tare vessel as well as examples to address frequently asked questions.
  7. Introduce a safety factor that addresses critical performance changes of the balance during routine usage.
  8. Add a Glossary to clarify the use of specific terms.
  9. Add Additional Information to ensure alignment of concepts and terminology.

 

 

SOURCES:

Pharmacopeial Forum (PF) | USP-NF (uspnf.com)

Latest posts

Back to all posts

Have questions on what Chemsafe can do for you?

26 Jun

Posted at 10:58h in Blog

The draft document “Data Integrity for In Vivo Bioavailability and Bioequivalence Studies” was published on the US FDA website at the beginning of April 2024. The document aims to assist applicants and marketing authorisation holders on achieving and maintaining data integrity for the clinical and bioanalytical part of bioavailability (BA) and bioequivalence (BE) studies for INDs (investigational new drug applications) submission, NDAs (new drug applications), ANDAs (abbreviated new drug applications), for the bioanalytical part of the clinical studies of BLAs (biologic licence applications) as well as for supplements and amendments to these marketing authorisations.

In addition, the recommendations in this guidance apply to the bioanalytical portion of nonclinical studies. The FDA also encourages applicants and testing sites to take these recommendations into consideration when conducting in vitro, pharmacology and toxicology studies.

 

SOURCES:

https://www.fda.gov/media/177404/download

Latest posts

Back to all posts

Have questions on what Chemsafe can do for you?

26 Jun

Posted at 10:50h in Blog

The draft guidance document “Handling and Retention of Bioavailability and Bioequivalence Testing Samples” is being distributed at March 2024

The guidance is intended to provide recommendations for study sponsors and/or drug manufacturers, contract research organizations (CROs), site management organizations (SMOs), clinical investigators, and independent third parties regarding the procedure for handling reserve samples from relevant bioavailability (BA) and bioequivalence (BE) studies, as required by 21 CFR 320.38 and 320.63.

The guidance highlights

  1. how the test article and reference standard for BA and BE studies should be distributed to the testing facilities,
  2. how testing facilities should randomly select samples for testing and material to maintain as reserve samples,
  3. how the reserve samples should be retained
  4. addresses the requirement at 21 CFR 320.38 (c) to retain sufficient quantity of reserve samples to allow FDA to perform five times all the release tests required in an application or supplemental application
  5. describes the conditions under which the Agency does not generally intend to take enforcement action against an applicant or CRO for retaining less than the quantity of reserve samples of the test article and reference standard that were used in the BA or BE study as specified in 21 CFR 320.38(c)

The guidance also clarifies the points addressed in §§ 320.38 and 320.63.

 

SOURCES:

https://www.fda.gov/media/71393/download

Latest posts

Back to all posts

Have questions on what Chemsafe can do for you?

26 Jun

Posted at 10:47h in Blog

The Reflection Paper discusses methodological aspects of non-interventional studies (NIS) using real-world data (RWD) to generate real-world evidence (RWE) for regulatory purposes.

The draft document on the use of real-world data in NIS to generate RWE is open for comment until 31 August 2024.

While clinical trials are the main source of evidence for the assessment of benefits and risks of medicinal products in marketing authorization procedures (they generally use randomisation, blinding, and a controlled environment), NIS are so far more accepted in post-authorization safety assessments.

Their use to assess the efficacy of medicinal products is hampered by methodological restrictions, such as the absence of randomisation, uncontrolled conditions, non-standardised treatments and uncertainties about data quality and completeness.

The reflection paper provides some examples where NIS using RWD have supported regulatory decision-making processes.

  • To perform post marketing monitoring, investigate safety concerns and evaluate the effectiveness of risk minimisation measures.
  • To describe patterns of drug utilisation.
  • To characterise disease epidemiology.
  • To validate outcome measures.
  • To support the feasibility assessments and the planning of non-interventional post authorisation safety, efficacy and medicinal products utilisation studies.
  • To compare patient characteristics of the study population to those of the clinical practice population in the real-world.
  • To understand the clinical context, by describing standards of care, variability in clinical practices and unmet medical needs.

 

Conclusions

Non-interventional studies play an increasing role in the generation of evidence to define and complete the totality of the evidence required for novel vaccines and treatments as well as label extension for existing therapies.

The wide variety in research objectives, study designs, data and methods present a challenge for standardisation; on the other hand, the regulatory authorities evaluating the evidence generated from NIS and the different stakeholder groups have different expectations regarding their use and fitness for purpose.

It is important to continue the effort to achieve a shared approach.

 

SOURCES:

https://www.ema.europa.eu/en/reflection-paper-use-real-world-data-non-interventional-studies-generate-real-world-evidence-scientific-guideline

Latest posts

Back to all posts

Have questions on what Chemsafe can do for you?

26 Jun

Posted at 10:39h in Blog
  • The use of Real-World Data (RWD) is increasingly embedded in the scientific evaluation of human medicines.The newly published EMA document on the topic (Guidance on Real-world evidence provided by EMA), explains:
    • how RWE, derived from analysis of RWD, can be useful in the context of regulatory decision-making,
    • what types of studies can be conducted,
    • how the EMA can help identify the best resources to address a research question.

     

    An analysis of the RWD provided by the EMA could help

    • to fill knowledge gaps;
    • to provide independent and transparent RWE sources;
    • to carry out specific analyses tailored to the individual case, e.g. to support the work of EMA’s scientific committees;
    • generate evidence more quickly, shortening the process steps that an MAH would have to comply with to obtain the corresponding study approved;
    • avoid unnecessary duplication and inefficiency that might be typical of studies done by industry.

    An overview of the three main areas in which RWE can support regulatory decision-making is shown in the figure below (taken from the document).

  • SOURCES:

    EMA’s Big data website.

Latest posts

Back to all posts

Have questions on what Chemsafe can do for you?

03 Apr

Posted at 10:39h in Blog
  • The ICH Q3C(R9) “Guideline for Residual Solvents” was revised using the ICH Minor Revision Procedure and reached Step 4 of the ICH Process on 24 January 2024.The document adopts a minor revision to section 3.4. concerning the consideration of solvent volatility for analytical methods.

    The Q3C ICH Guideline was finalised under Step 4 in July 1997 and provides recommendations on using of less toxic solvents in the manufacture of drug substances and dosage forms, as well as setting pharmaceutical limits for residual solvents (organic volatile impurities) in drug products.

    As part of the maintenance process, the Q3C Guideline incorporated the revision and inclusion of new Permitted Daily Exposure (PDE) levels as new toxicological data for solvents became available.

    In section 3.4 the guideline states that: “If only Class 3 solvents are present, a non-specific method such as loss on drying may be used, if the method is properly validated. The impact of solvent volatility on the test method should be considered in the validation.

    Validation of methods for residual solvents should conform to the current version of ICH guideline Q2 on Validation of Analytical Procedures”.

    SOURCES:

    ICH: News

Latest posts

Back to all posts

Have questions on what Chemsafe can do for you?